<DOC>
	<DOCNO>NCT02150876</DOCNO>
	<brief_summary>Bioresorbable polymer drug elute stent ( DES ) indisputable improvement first-generation DES promising result long-term adverse event . But thick polymer and/or strut may hinder deliverability . Complex procedure challenge stent deliverability stent delivery failure impact clinical prognosis . This registry aim assess immediate performance third-generation Synergy everolimus-eluting stent ( sEES ) 12-month clinical follow-up all-comer population .</brief_summary>
	<brief_title>SWiss Evaluation Bioabsorbable Polymer-coated Everolimus-eluting Coronary sTent</brief_title>
	<detailed_description>All consecutive patient treat SYNERGY stent institution prospectively include SWEET registry . Baseline procedural characteristic collect index procedure . Clinical follow-up perform 1 month 1 year clinic visit follow-up call . The study end point composite cardiac death ( CD ) , myocardial infarction ( MI ) target lesion revascularization ( TLR ) 1 year .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1.Patient treat everolimuseluting SYNERGYÂ® stent 1 . Patient legal guardian wo n't give consent use collect data</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>DES</keyword>
	<keyword>SDF</keyword>
	<keyword>MACE</keyword>
	<keyword>SYNERGY</keyword>
</DOC>